• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >Double‐blind placebo‐controlled trial of the effect of omalizumab on basophils in chronic urticaria patients
【24h】

Double‐blind placebo‐controlled trial of the effect of omalizumab on basophils in chronic urticaria patients

机译：双盲安慰剂对受控试验Omalizumab对慢性荨麻疹患者嗜碱性粒细胞的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary Background Omalizumab has been shown to be effective in treating chronic spontaneous urticaria ( CSU ). The reduction in Fcε RI receptor density on the surface of basophils and mast cells is thought to play a major role in its effectiveness. We conducted a double‐blind, randomized, placebo‐controlled trial to investigate the mode of action of omalizumab in patients with antihistamine‐resistant CSU . Methods Thirty patients were randomized in a 2:1 ratio to receive either 300?mg omalizumab or placebo. Four monthly applications of omalizumab/placebo were followed up with a visit 2?months after the last injection. The primary endpoint was the Fcε RI receptor density change on basophils. Results Omalizumab led to a significant reduction in Fcε RI receptor density on basophils as soon as 1?week after the first injection: baseline omalizumab vs placebo group, 80.31?±?47.18?×?103 vs 78.29?±?45.09?×?103 receptors/basophil?±? SD ; 1?week, 72.89?±?47.79?×?103 vs 27.83?±?20.87?×?103, P ?=?.001. This effect continued during the treatment phase and persisted for 2?months after the last injection: 93.81?±?56.50?×?103 vs 21.09?±?15.23?×?103, P ?=?.002. Values for basophil “releasability” and the basophil activation test ( CU ‐ BAT ) of patient serum using donor basophils were unchanged despite treatment: CU ‐ BAT , CD 63 10.75% (7.35) in the placebo group vs 8.35% (15.20) in the omalizumab group, P ?=?.778. Conclusion We demonstrated a rapid reduction of Fcε RI receptor density on basophils following treatment with omalizumab. Because CU ‐ BAT using well‐characterized, omalizumab‐na?ve donor basophils did not change during the treatment phase, autoreactive serum factors seem to remain unaltered. This points towards a cellular effect of omalizumab on basophils. To predict the omalizumab response time and to monitor disease, Fcε RI density and CU ‐ BAT might be promising cellular‐based assays.
机译：发明内容背景omalizumab已被证明可有效治疗慢性自发性荨麻疹（CSU）。据认为，嗜碱性粒细胞表面和肥大细胞表面上的FcεRI受体密度的降低是在其有效性中发挥重要作用。我们进行了双盲，随机的安慰剂对照试验，以研究奥拉司抑制抗组织患者的奥马拉姆布的作用方式。方法将30例患者在2：1的比例中随机化，以接受300μlMgomalizumab或安慰剂。 omalizumab /安慰剂的四个月度应用随访2个月后的第2个月。初级终点是嗜碱性粒细胞上的FCεRI受体密度变化。结果Omalizumab在第一次注射后1？周一周后，在嗜碱性粒细胞上发生显着降低：基线omalizumab VS安慰剂组，80.31？±47.18？×103 vs 78.29？±45.09？×103受体/嗜碱粒细胞？±？ SD; 1？周，72.89？±47.79？×103 vs 27.83？±20.87？×103，p？= 001。这种效果在治疗阶段继续持续，最后一次注射后持续2个月：93.81？±56.50？×103 vs 21.09？±15.23？×103，p？= 002。使用供体嗜碱性粒细胞的嗜碱性粒子“可释放性”的值和患者血清的嗜碱性激活试验（Cu - 蝙蝠），尽管治疗，安慰剂组中的CA - BAT，CD 63.75％（7.35）在8.35％（15.20）中omalizumab组，p？= 778。结论我们表明，在用omalizumab治疗后，对嗜碱性粒细胞的FcεRI受体密度的快速降低。因为Cu - 蝙蝠使用良好的表征，因此在治疗阶段不改变omalizumab-Na've嗜助碱，自身反应性血清因子似乎保持不变。这一点朝向嗜碱性粒细胞上的omalizumab细胞效果。为了预测omalizumab响应时间和监测疾病，FcεRI密度和Cu - 蝙蝠可能具有基于细胞的测定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号